Product Description
AGI-134 is being developed by Agalimmune for the treatment of patients with solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03593226?term=AGI-134&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Agalimmune
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Coronary Artery Disease|Oncology Solid Tumor Unspecified|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03593226 |
AGI-134.FIM.101 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2023-12-31 |
2025-02-15 |
Patient Enrollment|Primary Endpoints|Treatments |
|
ACTRN12621000665831p |
CHR-DHEA-testosterone-2012 | P2 |
Not yet recruiting |
Coronary Artery Disease |
2022-07-01 |
|||
2018-001032-22 |
Safety and Tolerability of AGI-134 | P2 |
Unknown status |
Other |
2022-05-19 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/18/2023 |
News Article |
Metastatic Melanoma Drug Market Scope, Trends, Size, Share, Prominent Players and Forecast 2031 |
|
05/17/2023 |
News Article |
BioLineRx to Report First Quarter 2023 Results on May 24, 2023 |
|
04/25/2023 |
News Article |
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement |
|
04/17/2023 |
News Article |
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma |